Incyte Corporation (INCY)

NasdaqGS Currently up 0.90 (+0.78%) in today's trading session

1 member of Congress has disclosed 2 trades in Incyte Corporation (INCY) via STOCK Act filings. The most recent disclosure was a sale by Gilbert Cisneros on 22 December 2020. Aggregate disclosed activity totals roughly $8K in purchases and $8K in sales (midpoint estimates from bracketed disclosure amounts).

Incyte Corporation is currently trading at $116.69, positioned at 94% of its 52-week range ($69.69 – $119.60).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$116.69
24h Change
+0.90 (+0.78%)
52 Week Range
$69.69$119.60
View on NASDAQ

Incyte Corporation Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for INCY

Select to highlight on chart
2 transactions
Compliance: 100%
Gilbert Cisneros22 Dec 202011 Jan 2021SaleStock$1,001 - $15,000N/A
Gilbert Cisneros16 Sept 202014 Oct 2020PurchaseStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$23.31B

Volume

956.12K

Beta

0.76

P/E Ratio

15.68

Fundamentals

EPS

$7.44

Div. Yield

Open

$115.04

Day Range

$114.50 — $117.48

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
William J. Meury
IPO Date
1993-11-04

Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a f...

Earnings

Next Report

Q2 2026

28 Jul

EPS Est.

$2.10

Rev. Est.

$1.5B

Days Until

5

Recent Quarters

Q1 202628 Apr
EPS$1.81
Beat 35.1%
Q4 202510 Feb
EPS$1.80
Miss 5.3%
Q3 202528 Oct
EPS$2.26
Beat 36.1%
Q2 202529 Jul
EPS$1.57
Beat 12.9%
Q1 202529 Apr
EPS$1.16
Beat 14.8%
Q4 202410 Feb
EPS$1.43
Miss 8.9%
Q3 202429 Oct
EPS$1.07
Miss 4.5%
Q2 202430 Jul
EPS$-1.82
Miss 333.3%
Q1 202430 Apr
EPS$0.64
Miss 23.8%
Q4 202313 Feb
EPS$1.06
Miss 8.6%
Q3 202331 Oct
EPS$1.10
Beat 0.9%
Q2 20231 Aug
EPS$0.99
Beat 19.3%
Q1 20232 May
EPS$0.37
Miss 56.5%
Q4 20227 Feb
EPS$0.62
Beat 5.1%
Q3 20221 Nov
EPS$0.60
Miss 16.7%
Q2 20222 Aug
EPS$1.01
Beat 27.9%
Q1 20223 May
EPS$0.55
Miss 3.5%
Q4 20218 Feb
EPS$0.10
Miss 88.1%
Q3 20212 Nov
EPS$1.18
Beat 55.3%
Q2 20213 Aug
EPS$0.80
Beat 8.1%
Q1 20214 May
EPS$0.67
Beat 3.1%
Q4 20209 Feb
EPS$0.93
Beat 13.4%
Q3 20205 Nov
EPS$0.23
Miss 68.1%
Q2 20204 Aug
EPS$1.24
Beat 42.5%
Q1 20205 May
EPS$-2.86
Miss 3675.0%
Q4 201913 Feb
EPS$0.65
Beat 14.0%
Q3 201929 Oct
EPS$0.82
Beat 26.1%
Q2 201930 Jul
EPS$0.75
Beat 53.1%
Q1 201930 Apr
EPS$0.62
Beat 55.0%
Q4 201814 Feb
EPS$0.40
Miss 13.0%
Q3 201830 Oct
EPS$0.38
Miss 5.0%
Q2 201831 Jul
EPS$0.26
Miss 23.5%
Q1 20181 May
EPS$-0.01
Miss 126.8%
Q4 201715 Feb
EPS$0.02
Beat 103.8%
Q3 201731 Oct
EPS$0.17
Beat 183.3%
Q2 20171 Aug
EPS$-0.06
Miss 20.0%
Q1 20174 May
EPS$-0.96
Beat 1.0%
Q4 201614 Feb
EPS$0.15
Beat 7.1%
Q3 20161 Nov
EPS$0.11
Beat 1594.9%
Q2 20169 Aug
EPS$0.19
Beat 1196.0%
Q1 20169 May
EPS$0.12
Miss 29.4%
Q4 201511 Feb
EPS$0.29
Beat 222.2%
Q3 20153 Nov
EPS$-0.22
Beat 46.3%
Q2 20154 Aug
EPS$-0.04
Beat 66.7%
Q1 201530 Apr
EPS$-0.11
Miss 83.3%
Q4 201412 Feb
EPS$-0.22
Miss 57.1%
Q3 201430 Oct
EPS$0.33
Beat 6033.8%
Q2 201431 Jul
EPS$-0.22
Miss 144.4%
Q1 20141 May
EPS$-0.21
Miss 10.5%
Q4 201312 Feb
EPS$-0.15
Miss 66.7%
Q3 201331 Oct
EPS$-0.14
Miss 7.7%
Q2 20131 Aug
EPS$0.05
Miss 28.6%
Q1 20132 May
EPS$-0.12
Beat 7.7%
Q4 201214 Feb
EPS$0.14
Beat 830.2%
Q3 20121 Nov
EPS$-0.10
Beat 52.4%
Q2 20122 Aug
EPS$0.03
Q1 201226 Apr
EPS$-0.36
Beat 21.7%
Q4 201115 Feb
EPS$-0.44
Miss 12.8%
Q3 201127 Oct
EPS$-0.42
Beat 6.7%
Q2 201128 Jul
EPS$-0.41
Miss 13.9%
Q1 20113 May
EPS$-0.21
Beat 34.4%
Q4 201010 Feb
EPS$0.24
Beat 26.3%
Q3 20109 Nov
EPS$-0.26
Beat 18.8%
Q2 20105 Aug
EPS$0.02
Beat 151.6%
Q1 20106 May
EPS$-0.30
Beat 6.3%
Q4 200918 Feb
EPS$-0.41
Miss 13.9%
Q3 20095 Nov
EPS$-0.44
Miss 10.0%
Q2 200930 Jul
EPS$-0.41
Beat 0.0%
Q1 20097 May
EPS$-0.41
Beat 0.0%
Q4 200818 Feb
EPS$-0.50
Miss 4.2%
Q3 20086 Nov
EPS$-0.48
Beat 4.0%
Q2 200829 Jul
EPS$-0.54
Miss 8.0%
Q1 200830 Apr
EPS$-0.47
Beat 0.0%
Q4 200714 Feb
EPS$-0.26
Beat 7.1%
Q3 20071 Nov
EPS$-0.29
Miss 7.4%
Q2 200726 Jul
EPS$-0.22
Beat 18.5%
Q1 20073 May
EPS$-0.26
Beat 0.0%
Q4 200615 Feb
EPS$-0.24
Beat 4.0%
Q3 20062 Nov
EPS$-0.19
Beat 20.8%
Q2 200627 Jul
EPS$-0.24
Beat 0.0%
Q1 20064 May
EPS$-0.21
Beat 19.2%
Q4 200516 Feb
EPS$-0.33
Miss 6.5%
Q3 20051 Nov
EPS$-0.36
Beat 5.3%
Q2 20051 Aug
EPS$-0.30
Beat 9.1%
Q1 20054 May
EPS$-0.24
Beat 27.3%
Q4 200428 Feb
EPS$-0.47
Miss 34.3%
Q3 20044 Nov
EPS$-0.35
Beat 18.6%
Q2 20044 Aug
EPS$-0.87
Miss 117.5%
Q1 20044 May
EPS$-0.52
Miss 15.6%
Q4 20032 Feb
EPS$-0.56
Miss 14.3%
Q3 20034 Nov
EPS$-0.60
Miss 53.9%
Q2 200330 Jul
EPS$-0.37
Beat 5.1%
Q1 20035 May
EPS$-0.36
Miss 28.6%
Q4 200219 Feb
EPS$-0.45
Miss 15.4%
Q3 200212 Nov
EPS$-0.45
Miss 21.6%
Q2 200225 Jul
EPS$-0.26
Beat 7.1%
Q1 20021 May
EPS$-0.20
Beat 4.8%
Q4 200113 Feb
EPS$-0.22
Beat 71.0%
Q3 200125 Oct
EPS$-0.27
Miss 42.1%
Q2 200119 Jul
EPS$-0.15
Beat 34.8%
Q1 200125 Apr
EPS$-0.16
Beat 42.9%
Q4 20001 Feb
EPS$-0.11
Beat 8.3%
Q3 200017 Oct
EPS$-0.12
Beat 0.0%
Q2 200018 Jul
EPS$-0.10
Beat 54.5%
Q1 200019 Apr
EPS$-0.13
Beat 53.6%
Q4 199926 Jan
EPS$-0.11
Beat 8.3%
Q3 199919 Oct
EPS$-0.19
Beat 0.0%
Q2 199914 Jul
EPS$-0.11
Beat 0.0%
Q1 199921 Apr
EPS$-0.04
Beat 50.0%
Q4 19983 Feb
EPS$0.12
Beat 20.0%
Q3 199814 Oct
EPS$0.08
Miss 20.0%
Q2 199814 Jul
EPS$0.10
Beat 11.1%
Q1 19988 Apr
EPS$0.08
Beat 0.0%
Q4 199713 Jan
EPS$0.09
Beat 28.6%
Q3 199715 Oct
EPS$0.06
Beat 0.0%
Q2 199715 Jul
EPS$0.04
Beat 18.1%
Q1 199717 Apr
EPS$0.02
Miss 19.6%
Q4 199626 Feb
EPS$0.00
Miss 64.2%
Q3 199624 Oct
EPS$-0.09
Q2 199625 Jul
EPS$-0.04
Miss 33.3%
Q1 199625 Apr
EPS$-0.04
Miss 21.4%
Q4 199522 Feb
EPS$-0.06
Beat 0.0%
Q3 199526 Oct
EPS$-0.09
Miss 50.0%
Q2 199528 Jul
EPS$-0.09
Miss 80.0%
Q1 199527 Apr
EPS$-0.06
Miss 20.0%
Q4 199423 Feb
EPS$-0.13
Miss 30.0%
Q3 199431 Dec
EPS$-0.19
Q1 199430 Jun
EPS$-0.10
Q4 199331 Mar
EPS$-0.09
Q3 199331 Dec
EPS$-0.05
Q2 199330 Sept
EPS$-0.05

No dividend data available for this stock.

Stock Splits

Split History

1 Sept 2000Stock Split
Ratio2:1
10 Nov 1997Stock Split
Ratio2:1

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about INCY

Which members of Congress have traded INCY?
1 member of Congress has disclosed 2 trade in Incyte Corporation (INCY) under the STOCK Act: Gilbert Cisneros.
When was INCY most recently disclosed by Congress?
The most recent INCY disclosure was a sale by Gilbert Cisneros on 22 December 2020.
What is the total disclosed congressional trading volume for INCY?
Members of Congress have disclosed approximately $8K in INCY purchases and $8K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in INCY?
This INCY page updates as soon as new STOCK Act disclosures are filed for Incyte Corporation. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.